BBM-P002 / Xiangya Hospital Central South University, Belief Biomed - LARVOL DELTA

A Phase I Multicenter Trial of a Novel Gene Therapy BBM-P002 for Parkinsons Disease (MDS Congress 2026) - No abstract available

Clinical • Gene therapy • P1 data • CNS Disorders • Movement Disorders • Parkinson's Disease

Dual-target gene therapy in Parkinson's disease: a multicenter phase 1 trial. (PubMed, Nat Med) - P1 | "In conclusion, intraputaminal delivery of BBM-P002 was safe and well tolerated in this phase 1 trial, supporting continued clinical development. ClinicalTrials.gov registration: NCT05822739 ."

Journal • P1 data • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Shanghai Xinzhi BioMed Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002) (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Xiangya Hospital of Central South University | Not yet recruiting ➔ Completed | Trial completion date: Dec 2028 ➔ Oct 2025 | Trial primary completion date: May 2025 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Shanghai Xinzhi BioMed Co., Ltd.

New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease